NuVasive Appoints New Chief Financial Officer and Announces Additional Manageme...(a Pacific region working from Tokyo Japa...),Health

Date:11/6/2009

a Pacific region, working from Tokyo, Japan. Mr. Tanaka joins NuVasive with a track-record of success in driving revenue and market share gains in the Asia Pacific region, having led the Medtronic Spinal, Biologics and Navigation Divisions to the #1 market share spot for the Asia Pacific region. He brings to NuVasive a wealth of experience in dealing with the unique dynamics of the Asia Pacific region.

• Stephan Siemers has been appointed Executive Vice President of Europe. Mr. Siemers will spearhead NuVasive's European sales and operations effort from Bremen, Germany. Stephan joins NuVasive following over fifteen years with Johnson & Johnson, where he most recently served as President of their international spine division. During his tenure, Mr. Siemers successfully reorganized the German sales and marketing structure, and was responsible for Europe, Middle East, Africa, Asia Pacific, Latin America, and Canada. His division enjoyed the largest and most consistent sales growth for the entire organization.
  

Alex Lukianov, Chairman and Chief Executive Officer, said, "As we increase focus on becoming the #4 global spine company and growing to a $1 billion spine franchise, we need a strong management team with the ambition and experience to drive the growth of operations and exemplify NuVasive's culture of Absolute Responsiveness and product innovation. I am excited to announce these additions to the depth and strategic composition of our senior management team. I look forward to working with this well-qualified leadership team to achieve our goals at Cheetah Speed."

About NuVasive

NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $4.6 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.5 billion gl
'/>"/>

SOURCE NuVasive, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference
2. NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results
3. NuVasive to Present at the JMP Securities Healthcare Focus Conference
4. Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors
5. Company Appoints New SVP, Marketing for PBM Business
6. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
7. Qforma Appoints Erin McLaughlin as Director, Field Operations
8. VitaminSpice Appoints Dr. Richard F. Seelig as Director
9. Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs
10. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
11. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs